e-learning
resources
Breathe
2014
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long-acting bronchodilators in COPD: where are we now and where are we going?
Cazzola Mario, Page Clive
Source:
Breathe 2014; 10:110-120
Journal Issue:
June
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Cazzola Mario, Page Clive. Long-acting bronchodilators in COPD: where are we now and where are we going?. Breathe 2014; 10:110-120
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
What to use INSTEAD of inhaled corticosteroids in COPD?
Source: Eur Respir J 2014; 44: 1391-1393
Year: 2014
Inhaled beta2-agonists in asthma management: an evolving story
Source: Breathe 2016; 12: 375-377
Year: 2016
Is it time to move away from short-acting beta-agonists in asthma management?
Source: Eur Respir J, 53 (4) 1802223; 10.1183/13993003.02223-2018
Year: 2019
Is there a problem with inhaled corticosteroid use in COPD?
Source: Virtual Congress 2020 – Airway diseases
Year: 2020
The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014
Optimising bronchodilator therapy in COPD: Who, why and when?
Source: International Congress 2019 – Personalised medicine in COPD: Matching the patient needs with the right care
Year: 2019
Inhaled corticosteroid combined with long-acting bronchodilator versus long-acting bronchodilator alone for older patients with COPD
Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation
Year: 2015
Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
Inhaled corticosteroids in COPD: the case against
Source: Eur Respir J 2009; 34: 13-16
Year: 2009
Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence?
Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents?
Year: 2020
Knowing when to stop: inhaled corticosteroids and COPD
Source: Eur Respir J 2015; 46: 1236-1238
Year: 2015
Are bronchodilator drugs really useful in COPD?
Source: Eur Respir J 2001; 18: Suppl. 33, 94s
Year: 2001
Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
Inhaled corticosteroids in COPD: a case in favour
Source: Eur Respir J 2009; 34: 10-12
Year: 2009
Inhaled beta2-agonists and death for asthma: can we overcome this risk?
Source: Annual Congress 2007 - Effect of long acting beta-agonists on severe asthma exacerbations and asthma-related deaths
Year: 2007
The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype
Source: International Congress 2015 – COPD and lung function: risk factors and outcomes
Year: 2015
First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients?
Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids
Year: 2004
Inhaled corticosteroids in treatment of patients with intermittent bronchial asthma: yes or no?
Source: Eur Respir J 2005; 26: Suppl. 49, 503s
Year: 2005
Anti-inflammatory therapy COPD: fenspiride and(or) theophylline
versus
inhaled corticosteroids?
Source: Annual Congress 2007 - Treatment of COPD
Year: 2007
Targeting neuropetides: from antiemetics to bronchodilators?
Source: Annual Congress 2012 - ERS Romain Pauwels Research Award Ceremony (supported by GlaxoSmithKline) followed by the Hot Topic "The nerves are back!"
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept